Sanjay Kulkarni, MD, FACS

Associate Professor of Surgery (Transplant) and of Medicine (Nephrology); Scientic Director, Yale Transplant Research Unit

Research Interests

Delivery of Health Care; Kidney; Kidney Failure, Chronic; Liver; Nephrology; Risk; Transplantation; Living Donors

Public Health Interests

Health care delivery; Health Care Management; Health Disparities; Health risk behaviors; Kidney Disease; Psychosocial risk factors

Research Organizations

Cancer Center, Yale



Vascular Biology and Therapeutics Program

Research Summary

Increasing living donation in a safe and effective manner is the only solution to the organ shortage. My research trys to examine how kidney donors assess risk and how this information can be better used by transplant centers when they evaluate possible living donors. Carrie Thieseen MD PhD (Yale) and I are currently conducting a muticenter study and are actively recruiting potential living donors.

I am also conducting a clinical study that tests an FDA approved system Airseal (Surgiquest, Inc.) to determine if we can reduce pain from the kidney donor surgery. The study in currently uderway and actively recruiting patients.

Unfortunately, kidneys don't last forever. There are new medications that may help some kidney transplant patients keep their kidney longer. We are conducting a clinical study using a complement inhibiator, eculizumab, to determine if we can stop antibodies from injuring kidneys. The study is still active, though it is closed to the recruitment of new patients.

Specialized Terms: The role of complement inhibition in kidney and liver transplantation; Methods to decrease pain for living kidney donors; UNOS & CMS regulations and compliance; Living donor risks and perceptions.

Extensive Research Description

I am interested in the role of complement inhibition in both kidney and liver transplantation. We are conducting an industry-sponsored study to assess if complement inbhibition with eculizumab can reduce antibody-mediated injury seen in kidney patients with donor-specific antibodies. I work with Jordan Pober MD PhD (Yale Immunobiology) on this study to assess what affect complement inhibition will have on graft endothelial cells. Given that donor specific antibodies may increase markers of endothelial cell activation, we are testing if complement inhibition will reduce activation and thus preserve graft function.

Living donation is a principal interest of mine, both clincally and academically. Previous work on living donor consenting practices and the need for better structured alibi's for donor has lead to a greater question on how transplant centers evaluate and approve living donors. Clearly, this requires a balance between donor autonomy and center malefiecne. I am working with Carrie Thiessen MD PhD (Yale) whose experience in normative research methods has resulted in a multicenter portocol designed to assess risk perception in living kidney donors.

1. Inhibition of Complement in Chronic Allograft Injury & its affect on Circulating Endothelial Cells.

2. Randomized Controlled Trial of Reducing Operative & Post-Operative Morbidity in Living Kidney Donors Utilizing Low Pressure, Limited Variability Pneumoperitoneum.

3. Burden of Illness in Highly Sensitized ESRD Patients & Patients Who Experience Acute Antibody-Mediated Rejection.

4. Balancing non-maleficence and autonomy in living kidney donors.

Selected Publications

Edit this profile

Contact Info

Sanjay Kulkarni, MD, FACS
Patient Care Locations
Yale Heart Failure and Transplant Saint Francis Care
1000 Asylum Avenue, Ste Suite 3201F

Hartford, CT 06105
Yale-New Haven Transplantation CenterYale Physicians Building
800 Howard Avenue, Ste 3rd floor

New Haven, CT 06519
Farnam Memorial Building
310 Cedar Street

New Haven, CT 06510
Mailing Address
PO Box 208062
New Haven, CT 06520-8062

Curriculum Vitae